B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Fortress Biotech (NASDAQ:FBIO) on Monday, setting a price target of $6, which is approximately 170.27% above the present share price of $2.22.
Mamtani expects Fortress Biotech to post earnings per share (EPS) of -$0.27 for the second quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Fortress Biotech, with an average price target of $8.5.
The analysts price targets range from a high of $11 to a low of $6.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $11.13 million and a net profit of -$30.38 million. The company's market cap is $180.69 million.
According to TipRanks.com, B.Riley FBR analyst Mayank Mamtani is a 5-star analyst with an average return of 10.5% and a 45.6% success rate.
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation, an independent brokerage company. The company was founded on June 28, 2006 in and is headquartered in New York, NY.